186 related articles for article (PubMed ID: 18266608)
1. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.
McGee CE; Tsetsarkin K; Vanlandingham DL; McElroy KL; Lang J; Guy B; Decelle T; Higgs S
J Infect Dis; 2008 Mar; 197(5):686-92. PubMed ID: 18266608
[TBL] [Abstract][Full Text] [Related]
2. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates.
McGee CE; Lewis MG; Claire MS; Wagner W; Lang J; Guy B; Tsetsarkin K; Higgs S; Decelle T
J Infect Dis; 2008 Mar; 197(5):693-7. PubMed ID: 18266603
[TBL] [Abstract][Full Text] [Related]
3. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
5. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
[TBL] [Abstract][Full Text] [Related]
6. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
[TBL] [Abstract][Full Text] [Related]
7. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.
Bhatt TR; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2000 Apr; 62(4):480-4. PubMed ID: 11220763
[TBL] [Abstract][Full Text] [Related]
8. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
9. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
[TBL] [Abstract][Full Text] [Related]
10. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Arroyo J; Monath TP; Miller BR
Med Vet Entomol; 2003 Sep; 17(3):235-43. PubMed ID: 12941006
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
[TBL] [Abstract][Full Text] [Related]
12. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antigen distribution and tissue tropisms of three phenotypically distinct yellow fever virus variants in orally infected Aedes aegypti mosquitoes.
McElroy KL; Girard YA; McGee CE; Tsetsarkin KA; Vanlandingham DL; Higgs S
Vector Borne Zoonotic Dis; 2008 Oct; 8(5):675-87. PubMed ID: 18494601
[TBL] [Abstract][Full Text] [Related]
14. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
[TBL] [Abstract][Full Text] [Related]
15. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
16. Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti.
Danet L; Beauclair G; Berthet M; Moratorio G; Gracias S; Tangy F; Choumet V; Jouvenet N
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007299. PubMed ID: 31412040
[TBL] [Abstract][Full Text] [Related]
17. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
18. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]